| 1 |
35386137 | Amiodarone, Verapamil, or Diltiazem Use With Direct Oral Anticoagulants and the Risk of Hemorrhage in Older Adults. | 2022 Mar |
1 |
| 2 |
35502121 | A comprehensive assessment of statin discontinuation among patients who concurrently initiate statins and CYP3A4-inhibitor drugs; a multistate transition model. | 2022 May 2 |
1 |
| 3 |
32803289 | Diltiazem on tacrolimus exposure and dose sparing in Chinese pediatric primary nephrotic syndrome: impact of CYP3A4, CYP3A5, ABCB1, and SLCO1B3 polymorphisms. | 2021 Jan |
2 |
| 4 |
33666764 | Drug Interactions with Antihypertensives. | 2021 Mar 5 |
1 |
| 5 |
32080863 | Predicting Clinical Effects of CYP3A4 Modulators on Abemaciclib and Active Metabolites Exposure Using Physiologically Based Pharmacokinetic Modeling. | 2020 Jul |
2 |
| 6 |
32329770 | Association of Oral Anticoagulants and Verapamil or Diltiazem With Adverse Bleeding Events in Patients With Nonvalvular Atrial Fibrillation and Normal Kidney Function. | 2020 Apr 1 |
1 |
| 7 |
30099888 | Clinical Safety Outcomes in Patients With Nonvalvular Atrial Fibrillation on Rivaroxaban and Diltiazem. | 2019 Jan |
1 |
| 8 |
30284597 | Interaction potential of the dual orexin receptor antagonist ACT-541468 with CYP3A4 and food: results from two interaction studies. | 2019 Feb |
1 |
| 9 |
29728928 | Effects of diltiazem, a moderate inhibitor of CYP3A4, on the pharmacokinetics of tamsulosin in different CYP2D6 genotypes. | 2018 May |
2 |
| 10 |
27149910 | Significant impacts of CYP3A4*1G and CYP3A5*3 genetic polymorphisms on the pharmacokinetics of diltiazem and its main metabolites in Chinese adult kidney transplant patients. | 2016 Jun |
5 |
| 11 |
27191770 | Induced next-day somnolence in an elderly patient taking suvorexant concomitantly with diltiazem. | 2016 Aug |
1 |
| 12 |
24604243 | Pharmacokinetic interactions between the orexin receptor antagonist almorexant and the CYP3A4 inhibitors ketoconazole and diltiazem. | 2014 May |
1 |
| 13 |
23381958 | Drug-drug interaction study of ACT-178882, a new renin inhibitor, and diltiazem in healthy subjects. | 2013 Mar |
1 |
| 14 |
27121666 | Effect of Multiple-Dose Diltiazem on the Pharmacokinetics of the Renin Inhibitor ACT-077825. | 2013 Apr |
1 |
| 15 |
22652334 | Assessment of drug-drug interactions caused by metabolism-dependent cytochrome P450 inhibition. | 2012 Jun 25 |
3 |
| 16 |
22828972 | Ranolazine-induced severe bladder hypotonia. | 2012 Sep |
1 |
| 17 |
21209240 | Effect of different durations and formulations of diltiazem on the single-dose pharmacokinetics of midazolam: how long do we go? | 2011 Nov |
1 |
| 18 |
21356216 | Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: role of phenolic hydroxyl groups in the resorcinol moiety. | 2011 Apr 11 |
1 |
| 19 |
21480191 | Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P-glycoprotein inhibitors. | 2011 Aug |
1 |
| 20 |
21835977 | Determination of time-dependent inactivation of CYP3A4 in cryopreserved human hepatocytes and assessment of human drug-drug interactions. | 2011 Nov |
1 |
| 21 |
22287853 | Two-way pharmacokinetic interaction studies between saxagliptin and cytochrome P450 substrates or inhibitors: simvastatin, diltiazem extended-release, and ketoconazole. | 2011 |
1 |
| 22 |
20150526 | Effects of concomitant therapy with diltiazem on the lipid responses to simvastatin in Chinese subjects. | 2010 Oct |
1 |
| 23 |
21084035 | Atorvastatin-induced acute elevation of hepatic enzymes and the absence of cross-toxicity of pravastatin. | 2010 Dec |
2 |
| 24 |
21112467 | Case report: delirium due to a diltiazem-fentanyl CYP3A4 drug interaction. | 2010 Nov-Dec |
2 |
| 25 |
19420129 | Semiphysiologically based pharmacokinetic models for the inhibition of midazolam clearance by diltiazem and its major metabolite. | 2009 Aug |
6 |
| 26 |
18558792 | Risk management of simvastatin or atorvastatin interactions with CYP3A4 inhibitors. | 2008 |
1 |
| 27 |
18589174 | Significant impact of gene polymorphisms on tacrolimus but not cyclosporine dosing in Asian renal transplant recipients. | 2008 Jun |
1 |
| 28 |
17293381 | Sequential metabolism is responsible for diltiazem-induced time-dependent loss of CYP3A. | 2007 May |
10 |
| 29 |
17304269 | [Interaction risk with statin switch]. | 2007 Feb 15 |
1 |
| 30 |
17392390 | Risk assessment for drug-drug interaction caused by metabolism-based inhibition of CYP3A using automated in vitro assay systems and its application in the early drug discovery process. | 2007 Jul |
1 |
| 31 |
16640453 | Clinical pharmacokinetics of ranolazine. | 2006 |
1 |
| 32 |
17178259 | Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. | 2006 Dec |
2 |
| 33 |
15801939 | Diltiazem inhibits human intestinal cytochrome P450 3A (CYP3A) activity in vivo without altering the expression of intestinal mRNA or protein. | 2005 Apr |
4 |
| 34 |
15858399 | Calcium channel blocker class heterogeneity: select aspects of pharmacokinetics and pharmacodynamics. | 2005 Apr |
2 |
| 35 |
16238231 | [Antihypertensive therapy and drug-drug interactions]. | 2005 Sep 14 |
1 |
| 36 |
15304427 | Cytochrome P450 3A4 is the major enzyme involved in the metabolism of the substance P receptor antagonist aprepitant. | 2004 Nov |
1 |
| 37 |
15370956 | Model for the drug-drug interaction responsible for CYP3A enzyme inhibition. I: evaluation of cynomolgus monkeys as surrogates for humans. | 2004 May |
1 |
| 38 |
15377640 | Differences in the inhibition of cytochromes P450 3A4 and 3A5 by metabolite-inhibitor complex-forming drugs. | 2004 Oct |
2 |
| 39 |
15555475 | Extended-release alfuzosin hydrochloride: a new alpha-adrenergic receptor antagonist for symptomatic benign prostatic hyperplasia. | 2004 Mar |
1 |
| 40 |
12610742 | Identification of epoxybergamottin as a CYP3A4 inhibitor in grapefruit peel. | 2003 Feb |
2 |
| 41 |
11744603 | Desacetyl-diltiazem displays severalfold higher affinity to CYP2D6 compared with CYP3A4. | 2002 Jan |
3 |
| 42 |
11422004 | Inhibitory effects of verapamil and diltiazem on simvastatin metabolism in human liver microsomes. | 2001 May |
2 |
| 43 |
11560871 | Effects of CYP3A4 inhibition by diltiazem on pharmacokinetics and dynamics of diazepam in relation to CYP2C19 genotype status. | 2001 Oct |
3 |
| 44 |
10640508 | Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. | 2000 Feb |
4 |
| 45 |
10741630 | The interaction of diltiazem with simvastatin. | 2000 Mar |
3 |
| 46 |
10950845 | An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. | 2000 Sep |
5 |
| 47 |
10971313 | Intravenous diltiazem and CYP3A-mediated metabolism. | 2000 Sep |
1 |
| 48 |
11038161 | Automated definition of the enzymology of drug oxidation by the major human drug metabolizing cytochrome P450s. | 2000 Nov |
1 |
| 49 |
11151747 | CYP2D6 is involved in O-demethylation of diltiazem. An in vitro study with transfected human liver cells. | 2000 Nov |
1 |
| 50 |
10385214 | Halofantrine metabolism in microsomes in man: major role of CYP 3A4 and CYP 3A5. | 1999 Apr |
1 |